Leukemia, Myeloid, Acute: all 3,035 studies

Page 19 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.

• A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT04443751Phase 1
• JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell TransplantationCompletedNCT04429191Phase 1
• Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.TerminatedNCT04425655Phase 2
• Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAMLCompletedNCT04424147Phase 2
• Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid LeukemiaActive, not recruitingNCT04415008Phase 2
• Endogenous Retroviruses in Acute Myeloid LeukemiaWithdrawnNCT04406207
• Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AMLTerminatedNCT04402723Phase 1
• Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT04402541Phase 1
• Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)WithdrawnNCT04395092Phase 2
• Outcomes of Acute Myeloid Leukemia PatientsStatus unknownNCT04392310
• Quality of Life Model for Older Patients With AMLActive, not recruitingNCT04380441
• Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)Status unknownNCT04373395Not applicable
• Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid LeukemiaStatus unknownNCT04369287
• Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant CyclophosphamideWithdrawnNCT04361058Phase 1
• Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AMLWithdrawnNCT04354025Phase 2
• Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid LeukemiaStatus unknownNCT04353479Phase 2
• CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid LeukemiaStatus unknownNCT04351022Phase 1/2
• Natural Killer-cell Therapy for Acute Myeloid LeukemiaTerminatedNCT04347616Phase 1/2
• Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid LeukemiaTerminatedNCT04342962Phase 2
• A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid LeukemiaTerminatedNCT04336982Phase 1
• Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)CompletedNCT04330820Phase 1/2
• Safety of Expanded Haploidentical Natural Killer Cells for LeukemiaCompletedNCT04327037Phase 1
• Panobinostat Maintenance After HSCT fo High-risk AML and MDSTerminatedNCT04326764Phase 3
• Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)CompletedNCT04326023
• Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm TreatmentCompletedNCT04321161Early Phase 1
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Natural Killer Cell (CYNK-001) Infusions in Adults with AMLTerminatedNCT04310592Phase 1
• Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaWithdrawnNCT04296214
• Immunophenotyping and Xist Gene in AMLStatus unknownNCT04288739
• Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCTActive, not recruitingNCT04284228Phase 1/2
• A Study of TAS1440 With ATRA in Subjects With r/r AMLTerminatedNCT04282668Phase 1
• Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)SuspendedNCT04278768Phase 1/2
• A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/NeoplasmsStatus unknownNCT04272957Phase 1
• A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated CancersTerminatedNCT04272203Phase 1
• Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity ScreeningCompletedNCT04267081Phase 2
• CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT04265963Phase 1/2
• AML/MDS Drug Sensitization by in Vivo Chemotherapy AdministrationActive, not recruitingNCT04263181
• Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute LeukemiaActive, not recruitingNCT04262843Phase 2
• Analysis of T Cell Metabolism in Acute Myeloid Leukemia PatientsCompletedNCT04259372
• Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AMLStatus unknownNCT04254640Phase 2
• A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian FederationCompletedNCT04253314
• Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT04250051Phase 1
• Study of Azacitidine Combined With Homoharringtonie Based Regimens in AMLStatus unknownNCT04248595Phase 2
• A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive TreatmentCompletedNCT04241549Phase 1
• Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital StayStatus unknownNCT04240600Not applicable
• Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute LeukemiaActive, not recruitingNCT04232241Phase 2
• Acute Myeloid Leukemia Real World Treatment PatternsWithdrawnNCT04230564
• Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic MalignanciesTerminatedNCT04230265Phase 1
• Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Active, not recruitingNCT04229979Phase 3
• A Safety Study of SEA-CD70 in Patients With Myeloid MalignanciesActive, not recruitingNCT04227847Phase 1
• NK Cell Infusion for Patients With Acute Myeloid LeukemiaStatus unknownNCT04221971Phase 1
• Trial Testing Safety of IL-21 NK Cells for Induction of R/R AMLCompletedNCT04220684Phase 1
• Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 AntigenActive, not recruitingNCT04219163Phase 1
• A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCTActive, not recruitingNCT04217278Phase 2/3
• PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid LeukemiaStatus unknownNCT04215822
• Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual DiseaseStatus unknownNCT04209712Early Phase 1
• Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT04207190Phase 1
• Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 MutationActive, not recruitingNCT04203316Phase 2
• A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT04202003Phase 1/2
• Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid NeoplasmsTerminatedNCT04196010Phase 1
• Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04190550Phase 1
• Resiliency in Older Adults Undergoing Bone Marrow TransplantCompletedNCT04188678
• Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT04188405Phase 2
• Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)Status unknownNCT04187495Phase 1
• A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 MutationCompletedNCT04176393Phase 1
• Cord Blood Microtransplantation for Treatment of Acute Myeloid LeukemiaStatus unknownNCT04174586Phase 1
• TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With BortezomibCompletedNCT04173585Phase 2
• Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCTCompletedNCT04173533Phase 3
• Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous LeukemiaTerminatedNCT04172844Phase 1
• D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly PatientsStatus unknownNCT04168138Not applicable
• NTX-301 in MDS/AMLCompletedNCT04167917Phase 1
• Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell TransplantActive, not recruitingNCT04167683
• Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDSTerminatedNCT04166929Phase 2
• Integrating Geriatric Assessment for Older Patients Diagnosed With Acute Myelogenous LeukemiaCompletedNCT04158726Not applicable
• A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)TerminatedNCT04155580Phase 1
• Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid LeukemiaActive, not recruitingNCT04150887Phase 1
• Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AMLCompletedNCT04139434Phase 1
• Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid LeukemiaStatus unknownNCT04133220
• Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeActive, not recruitingNCT04128748Phase 1/2
• Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant SettingActive, not recruitingNCT04128501Phase 2
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)TerminatedNCT04113616Phase 1/2
• A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First TreatmentStatus unknownNCT04112589Phase 1/2
• Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)CompletedNCT04107727Phase 2
• Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid LeukemiaWithdrawnNCT04106076Phase 1
• A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT04100330Phase 2
• Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)TerminatedNCT04093505Phase 3
• Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard ChemotherapyActive, not recruitingNCT04090736Phase 3
• Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML PatientsStatus unknownNCT04087967Phase 3
• IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaActive, not recruitingNCT04086264Phase 1/2
• Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60Status unknownNCT04083911Phase 3
• Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory LeukaemiaCompletedNCT04082286Phase 1
• Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After ChemotherapyCompletedNCT04081753Not applicable
• LY3214996 in Patients With AML Who Are Not Candidates for Standard TherapyCompletedNCT04081259Phase 1
• A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid LeukemiaCompletedNCT04075747Phase 1
• Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting BCL-2Status unknownNCT04070807
• IA14 Induction in Young Acute Myeloid LeukemiaStatus unknownNCT04069208Phase 2
• First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT04067336Phase 1/2
• Randomized Clinical Study Assessing Haplo vs. URD in AMLTerminatedNCT04067180Not applicable
• AZA + Venetoclax as Maintenance Therapy in Patients With AML in RemissionTerminatedNCT04062266Phase 2
• Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment ResultsStatus unknownNCT04060485

← Leukemia, Myeloid, Acute overview